Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
SUPERNUS PHARMACEUTICALS, INC.
Bear Case (25th pct.)
-88.7% vs price
Base Case (Median)
-81.2% vs price
Bull Case (75th pct.)
-80.2% vs price
◇ = Current price | | Bear | Base | Bull
| Method | Est. Value | vs Price | Weight |
|---|---|---|---|
| DCF (Discounted Cash Flow) | $1.65 | -96.1% | High (40%) |
| EV/EBITDA | $8.83 | -79.2% | Medium (20%) |
| EV/FCF | $7.98 | -81.2% | Medium (20%) |
Based on 3 out of 7 methods, SUPN appears overvalued at the current price of $42.38. The base case fair value of $7.98 implies 81.2% downside.
Bear/base/bull cases represent the 25th, 50th, and 75th percentile of available method estimates. This is not financial advice. Valuation is inherently uncertain.